Procedure reshapes cornea using microwave technology


A procedure that uses microwaves to alter corneal refraction may be alternative to LASIK in myopia patients

A refractive procedure (Keraflex, Avedro) fifteen years in the making uses microwave technology to reshape the cornea. It is currently in initial clinical testing.

The technique changes the corneal refraction without removing stromal tissue or creating a flap. The procedure may be promising for paients with low and moderate levels of myopia who are squeamish about undergoing a conventional refractive surgery procedure in which corneal tissue is removed.

The procedure focuses microwave energy that is applied in annular pattern to the corneal midperiphery.

Speaking to the potential market for this type of procedure, Dr Muller said that a survey about refractive vision correction for myopia polled 2,400 consumers for specific reasons for not undergoing a refractive procedure. The top three factors cited by this group for not undergoing a refractive procedure. The top three factors cited by this group for not undergoing LASIK were 66% who were: "Nervous about poor results," 54% who did not like the ideas of "cutting the eye," and 45% cited just plain "fear."

The focused energy used in the procedure, delivered in one pulse of less than 100µs, causes collagen shrinkage and corneal flattening , which does not permanently alter the cornea or require removal of corneal tissue.

The procedure is performed under the control of a microprocessor during application of electrodes to the eye. The electrodes, which can vary in thickness and the degree by which they are separated on the corneal surface, are applied to the eye outside of the visual axis.

A coolant is delivered in micropulses to control the temperature of the cornea, after which the microwave energy is applied to the cooled corneal area. The collagen in the area treated with microwave energy shrinks, which results in predictable flattening of the central cornea.

"By balancing the microwave field intensity and cooling period, the peak temperature generated can be driven to predetermined depths within the corneal stroma, causing changes in the collagen without damage to the corneal epithelium," said Dr John Marshall, FRCPath, FRCOphth (Hon), the Frost Professor of Ophthalmology and chairman, Department of Ophthalmology, Kings College, St Thomas' Hospital, London and lead scientific advisor.

"Such modifications to collagen fibrils result in changes in the refractive properties of the cornea," he added. "By varaying the depth and diameter of the induced collagen variations, controlled refractive changes may be introduced of different signs and magnitude. Thus, refractive errors can be corrected without removing any tissue. In vitro experiments have been conducted in both animal and human eyes using a model system capable of preserving wound healing for 4 to 6 weeks postexposure."

Histopathologic studies indicate that the induced treatment changes consist of altered collagen fibrils with modifications in the local geometry of the lamellae, Dr Marshall said. These areas of change undergo rapid wound healing in which the matrix assumes a normal appearance and the collagen retains its newly induced curvature. A transient superficial haze apparent immediately after exposure is lost within a minutes aftr treatment. By varying the adminstered parameters a systematic change in refraction was achieved, he said.

Dr Marguerite McDonald, a member of the medical advisory board and clinical associate professor of ophthalmology, Department of Ophthalmology, New York University, New York and adjunct clinical professor of ophthalmology, Tulane University, New Orleans, commented on the procedure.

"It is early in the game vis-a-vis the clinical trials which are being conducted outside the United States. Nevertheless, the results are encouraging," she said. US clinical trials were expected to begin shortly.

Related Videos
J. Morgan Micheletti, MD, speaks at the 2024 ASCRS meeting
Dr William Wiley of Cleveland Eye Clinic, Northeast Ohio
Filomena Ribeiro, MD, PhD, FEBO, speaks at the 2024 ASCRS meeting
A screenshot of Dr Filomena Ribeiro, president of the ESCRS
© 2024 MJH Life Sciences

All rights reserved.